ライフサイエンスコーパス: antiphospholipid

1 recurrence is in most cases associated with antiphospholipid A2 receptor antibodies.

2 lantation, including the prognostic value of antiphospholipid A2 receptor, the risk of living-related

3 Antiphospholipid Ab have been shown to promote thrombosi

4 vity of eight patient-derived monoclonal IgG antiphospholipid Ab with FXa and the presence of IgG ant

5 ty in the antiphospholipid syndrome (APS) is antiphospholipid Ab-mediated upregulation of tissue fact

6 In the antiphospholipid syndrome (APS), antiphospholipid Abs (aPL) bind to anionic phospholipids

7 We previously reported that some human antiphospholipid Abs (aPL) in patients with the antiphos

8 Antiphospholipid Abs (APLAs) are associated with thrombo

9 f thrombotic events among women positive for antiphospholipid Abs (n = 517), women carrying the F5 60

10 s currently recognized as the main target of antiphospholipid Abs responsible for complement activati

11 eta(2)GPI) is the major antigenic target for antiphospholipid Abs.

12 munosorbent assay (ELISA) and immunoblot for antiphospholipid and A2 antibodies.

13 Other autoreactive IgM antibodies, such as antiphospholipid and anti-Sm, did not alter the patholog

14 One mechanism by which circulating antiphospholipid/anti-beta2GPI antibodies may promote th

15 trap (NET) release is one mechanism by which antiphospholipid antibodies (aPL Abs) effect thrombotic

16 erosclerosis have an increased prevalence of antiphospholipid antibodies (aPL) and antibodies to oxid

17 Although antiphospholipid antibodies (aPL) are associated with ar

18 Pathogenic antiphospholipid antibodies (aPL) bind the self antigen

19 In antiphospholipid syndrome (APS), antiphospholipid antibodies (aPL) binding to beta2 glyco

20 The presence of antiphospholipid antibodies (aPL) has been associated wi

21 Antiphospholipid antibodies (aPL) have been shown to ind

22 Antiphospholipid antibodies (aPL) have thrombogenic prop

23 To test the hypothesis that some antiphospholipid antibodies (aPL) in patients with the a

24 phospholipid syndrome (APS), suggesting that antiphospholipid antibodies (aPL) may bind platelets, ca

25 Serum antiphospholipid antibodies (aPL) were identified by ant

26 ients had APS, 24 patients were positive for antiphospholipid antibodies (aPL), and 19 patients had S

27 a condition characterized by the presence of antiphospholipid antibodies (aPL), often suffer pregnanc

28 d laboratory confirmation of the presence of antiphospholipid antibodies (aPL).

29 hat has been associated with the presence of antiphospholipid antibodies (aPL).

30 poorly known, particularly in the absence of antiphospholipid antibodies (APL).

31 ipid syndrome (APS), our approach focused on antiphospholipid antibodies (aPL).

32 Laboratory evidence of antiphospholipid antibodies (APLA) in patients with a fi

33 Patients with antiphospholipid antibodies (APLAs) are at increased ris

34 recurrent pregnancy loss in the presence of antiphospholipid antibodies (APLAs).

35 is and recurrent fetal loss in patients with antiphospholipid antibodies (APLAs).

36 se it binds phospholipids, it is a target of antiphospholipid antibodies (aPLs) in antiphospholipid s

37 Fetal loss induced by antiphospholipid antibodies (aPLs) in mice is a compleme

38 There are few data on the relationship of antiphospholipid antibodies (aPLs) to pathologically pro

39 Antiphospholipid antibodies (aPLs) with complex lipid an

40 (P = 0.04) and were also more likely to have antiphospholipid antibodies (lupus anticoagulant) (P = 0

41 Antiphospholipid antibodies and CRP support the role of

42 mbocytopenia associated with the presence of antiphospholipid antibodies and persistently positive an

43 lar endothelial cell dysfunction mediated by antiphospholipid antibodies and subsequent complement sy

44 mbotic status of APS patients induced by IgG-antiphospholipid antibodies and the beneficial effects o

45 Antiphospholipid antibodies are commonly found in patien

46 (n = 513; LMWH + LDA) and women negative for antiphospholipid antibodies as controls (n = 791; no tre

47 n with aspirin is justified in patients with antiphospholipid antibodies but without a prior history

48 Antiphospholipid antibodies can be detected in roughly 5

49 bset of periodontitis patients with elevated antiphospholipid antibodies could represent a subgroup a

50 Anticoagulation, prednisone dose, and antiphospholipid antibodies did not significantly impact

51 Antiphospholipid antibodies disrupt AnxA5 binding, there

52 The antiphospholipid antibodies found in this syndrome are d

53 gs of yellow scleral plaques and circulating antiphospholipid antibodies have been proposed as marker

54 onucleoprotein antibodies in 26 percent, and antiphospholipid antibodies in 18 percent.

55 PS) is defined by the persistent presence of antiphospholipid antibodies in patients with a history o

56 een conducted to determine the prevalence of antiphospholipid antibodies in patients with retinal vas

57 Antiphospholipid antibodies in SLE are associated with m

58 Antiphospholipid antibodies including anticardiolipin an

59 The presence of pretransplant antiphospholipid antibodies increases risk of graft thro

60 of thrombosis and gestational morbidity with antiphospholipid antibodies is termed antiphospholipid s

61 e setting of persistently positive levels of antiphospholipid antibodies measured on 2 different occa

62 The molecular pathways through which antiphospholipid antibodies modulate the mTORC pathway w

63 HCQ reversed the effect of antiphospholipid antibodies on AnxA5 and restored AnxA5

64 otein I (beta(2)-GPI) is a major antigen for antiphospholipid antibodies present in patients with the

65 Antiphospholipid antibodies should be sought in all pati

66 r V Leiden, prothrombin 20210A mutation, and antiphospholipid antibodies significantly increases a pa

67 the molecular and intracellular events that antiphospholipid antibodies trigger in target cells, as

68 actions and the intracellular signaling that antiphospholipid antibodies trigger, new therapeutic and

69 rrent pregnancy loss includes measurement of antiphospholipid antibodies under the perception that th

70 Rates of antiphospholipid antibodies were low, comparable to thos

71 No antiphospholipid antibodies were present in the patient'

72 Antiphospholipid antibodies were present(defined as IgG

73 Eighteen women with antiphospholipid antibodies who had refractory pregnancy

74 ion on biopsy as compared with patients with antiphospholipid antibodies who were not receiving sirol

75 n I (beta2GPI; the major autoantigen for the antiphospholipid antibodies) and the homologous catalyti

76 c lupus erythematosus (SLE), 2 patients with antiphospholipid antibodies, and 3 other patients, but a

77 re corticosteroid treatment, the presence of antiphospholipid antibodies, and acute thrombocytopenia.

78 Antinuclear, antiphospholipid antibodies, anti-Ro, and anti-La antibo

79 y of stroke, migraine with aura, circulating antiphospholipid antibodies, discontinuation of antiplat

80 ment, but also regarding the pathogenesis of antiphospholipid antibodies, has emerged.

81 nd/or pregnancy morbidity in the presence of antiphospholipid antibodies, including anti-beta2-glycop

82 thrombosis, fetal loss, and the presence of antiphospholipid antibodies, including anti-beta2-glycop

83 patients with key clinical manifestations of antiphospholipid antibodies, including patients with ant

84 ion discusses novel pathogenic mechanisms of antiphospholipid antibodies, including the activation of

85 ll lines, wherein HCQ reduced the binding of antiphospholipid antibodies, increased cell-surface AnxA

86 n of disease, hypertension, body mass index, antiphospholipid antibodies, kidney disease, acute throm

87 or V antibody not related to the presence of antiphospholipid antibodies, which is responsible for th

88 ished by the 13th International Committee on Antiphospholipid Antibodies.

89 or at risk of, thrombosis in the setting of antiphospholipid antibodies.

90 cular complications of lupus associated with antiphospholipid antibodies.

91 ffective for nonthrombotic manifestations of antiphospholipid antibodies.

92 coprotein I (beta2GPI), the main antigen for antiphospholipid antibodies.

93 after renal transplantation in patients with antiphospholipid antibodies.

94 disease activity, emotional disturbance, and antiphospholipid antibodies.

95 recurrent pregnancy failure associated with antiphospholipid antibodies.

96 ity in the presence of persistently positive antiphospholipid antibodies.

97 hrombotic risk in asymptomatic patients with antiphospholipid antibodies.

98 al anticoagulant and fibrinolytic systems by antiphospholipid antibodies.

99 factor VII mutation, factor II mutation, and antiphospholipid antibodies.

100 w that ApoER2 is involved in pathogenesis of antiphospholipids antibodies.

101 to PON1 activity, SLE risk, lupus nephritis, antiphospholipid antibody (aPL) positivity, and carotid

102 action of WIG in an in vivo murine model of antiphospholipid antibody (aPL)-induced thrombosis and e

103 sis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (th

104 y was to evaluate the safety of rituximab in antiphospholipid antibody (aPL)-positive patients with n

105 physicians in the management of persistently antiphospholipid antibody (aPL)-positive patients.

106 Although not all patients with elevated antiphospholipid antibody (aPLA) levels develop complica

107 The Antiphospholipid Antibody Acetylsalicylic Acid (APLASA)

108 ress with regard to the relationship between antiphospholipid antibody and its target, beta-2-glycopr

109 Antiphospholipid antibody profiles and clinical outcome

110 End-stage renal disease (ESRD) patients with antiphospholipid antibody syndrome (APAS) remain at high

111 Antiphospholipid antibody syndrome (APS) is a complex au

112 Patients with the antiphospholipid antibody syndrome (APS) often experienc

113 potential role of new oral anticoagulants in antiphospholipid antibody syndrome (APS) remains uncerta

114 New antibody tests for antiphospholipid antibody syndrome are available with in

115 understanding of the pathophysiology behind antiphospholipid antibody syndrome has led to novel appr

116 idelines for the treatment and management of antiphospholipid antibody syndrome have been established

117 The diagnostic criteria of antiphospholipid antibody syndrome have been reviewed an

118 The antiphospholipid antibody syndrome is an important cause

119 Antiphospholipid antibody syndrome with valvular vegetat

120 plant-associated thrombotic microangiopathy, antiphospholipid antibody syndrome, myasthenia gravis, a

121 er pertaining to anticoagulant choice, as in antiphospholipid antibody syndrome, or to addressing a n

122 d cause valvular vegetations associated with antiphospholipid antibody syndrome, which would be a new

123 pholipid antibodies, including patients with antiphospholipid antibody syndrome.

124 e appropriate laboratory results make up the antiphospholipid antibody syndrome.

125 l hemolytic uremic syndrome and catastrophic antiphospholipid antibody syndrome.

126 Routine laboratory, autoantibody, and antiphospholipid antibody testing was performed in the h

127 reincubation of healthy monocytes before IgG-antiphospholipid antibody treatment decreased oxidative

128 olytic anemia, anti-double-stranded DNA, and antiphospholipid antibody were associated with thrombocy

129 levant risk factors including renal disease, antiphospholipid antibody, and anti-Ro/SS-A and anti-La/

130 imer test after stopping anticoagulation, an antiphospholipid antibody, low risk of bleeding, and pat

131 utcome in women with a history of refractory antiphospholipid antibody-associated pregnancy loss(es)

132 r assessment in the management of refractory antiphospholipid antibody-related pregnancy loss(es), al

133 cardiac foramen ovale, or elevated levels of antiphospholipid antibody.

134 ctive protein (CRP), and the presence of any antiphospholipid antibody.

135 eutrophil cytoplasmic, antiendothelial cell, antiphospholipid/anticardiolipin and antithyroid antibod

136 nancy loss and thrombosis in the presence of antiphospholipid (aPL) Ab's.

137 , and vascular thrombosis in the presence of antiphospholipid (aPL) Abs.

138 recurrent pregnancy loss in the presence of antiphospholipid (aPL) antibodies and is generally treat

139 Fetal loss in patients with antiphospholipid (aPL) antibodies has been ascribed to t

140 Antiphospholipid (aPL) antibodies recognize receptor-bou

141 Using different mouse monoclonal and human antiphospholipid (aPL) antibodies, we developed a new an

142 hrombocytopenia occurring in the presence of antiphospholipid (aPL) antibodies.

143 The antiphospholipid (aPL) antibody syndrome is an autoimmun

144 Recently, human antiphospholipid (aPL) monoclonal antibodies (mAbs) have

145 iated with reduced risk of thrombosis in the antiphospholipid (aPL) syndrome (APS) and, in an animal

146 The antiphospholipid (aPL) syndrome is an acquired autoimmun

147 The antiphospholipid (aPL) syndrome is an autoimmune conditi

148 Antiphospholipid (aPL)/anti-beta(2) glycoprotein I (anti

149 stically significant, reductions of clinical antiphospholipid assays.

150 of systematically testing for C. burnetii in antiphospholipid-associated cardiac valve disease, and p

151 Antiphospholipid autoantibodies (aPLs) are prevalent in

152 s and gestational morbidity in patients with antiphospholipid autoantibodies (aPLs).

153 These findings identify antiphospholipid autoantibodies as a potential patient-s

154 antinuclear antibodies: one had anti-RNP and antiphospholipid autoantibodies, and the other had anti-

155 e, and performing early echocardiography and antiphospholipid dosages in patients with acute Q fever.

156 Similar reversals of antiphospholipid-induced abnormalities were measured on

157 In conclusion, HCQ reversed antiphospholipid-mediated disruptions of AnxA5 on PLBs a

158 s are reported in approximately one third of antiphospholipid-positive patients.

159 A high percentage of patients with antiphospholipid syndrome (41%) and systemic lupus eryth

160 y complications: a mouse model of obstetrics antiphospholipid syndrome (APS) and a mouse model of pre

161 Male (NZW x BXSB)F(1) mice develop antiphospholipid syndrome (APS) and proliferative glomer

162 Patients with antiphospholipid syndrome (APS) are at a high risk of de

163 Pregnant women with antiphospholipid syndrome (APS) are at a high risk of ob

164 Using antiphospholipid syndrome (APS) as a model, we demonstra

165 iphospholipid Abs (aPL) in patients with the antiphospholipid syndrome (APS) bind to the homologous e

166 Xa reactive IgG isolated from patients with antiphospholipid syndrome (APS) display higher avidity b

167 lar weight heparin [LDA+LMWH]) for obstetric antiphospholipid syndrome (APS) does not prevent life-th

168 the pathogenesis, diagnosis and treatment of antiphospholipid syndrome (APS) from current literature.

169 The classification criteria for both SLE and antiphospholipid syndrome (APS) have been updated, and u

170 The antiphospholipid syndrome (APS) is a systemic autoimmune

171 Antiphospholipid syndrome (APS) is an autoimmune disease

172 Antiphospholipid syndrome (APS) is an autoimmune disorde

173 major mechanism of hypercoagulability in the antiphospholipid syndrome (APS) is antiphospholipid Ab-m

174 The antiphospholipid syndrome (APS) is characterized by recu

175 The antiphospholipid syndrome (APS) is characterized by recu

176 Antiphospholipid syndrome (APS) is characterized by recu

177 The antiphospholipid syndrome (APS) is characterized by thro

178 Antiphospholipid syndrome (APS) is defined by recurrent

179 The antiphospholipid syndrome (APS) is defined by the persis

180 The antiphospholipid syndrome (APS) is defined by thrombosis

181 Antiphospholipid syndrome (APS) is defined by thrombosis

182 Antiphospholipid syndrome (APS) is well recognized as an

183 r pregnancy loss and either purely obstetric antiphospholipid syndrome (APS) or inherited thrombophil

184 olipid antibodies (aPL) in patients with the antiphospholipid syndrome (APS) recognize a conformation

185 e prothrombotic or proinflammatory status of antiphospholipid syndrome (APS) remain unknown.

186 ibodies test can identify some patients with antiphospholipid syndrome (APS) that are negative for ot

187 for women with the purely obstetric form of antiphospholipid syndrome (APS) treated with prophylacti

188 mmunoglobulin G (IgG) from patients with the antiphospholipid syndrome (APS) upon monocyte activation

189 Women with antiphospholipid syndrome (APS), a condition characteriz

190 get of antiphospholipid antibodies (aPLs) in antiphospholipid syndrome (APS), a life-threatening auto

191 In the antiphospholipid syndrome (APS), antiphospholipid Abs (a

192 In antiphospholipid syndrome (APS), antiphospholipid antibo

193 e clinical phenotype, including catastrophic antiphospholipid syndrome (APS), atypical presentations

194 linked to autoimmune disorders, particularly antiphospholipid syndrome (APS), in which autoantibodies

195 re COVID-19 and resemble hypercoagulation of antiphospholipid syndrome (APS), our approach focused on

196 sis and thrombocytopenia are features of the antiphospholipid syndrome (APS), suggesting that antipho

197 patients with non-criteria manifestations of antiphospholipid syndrome (APS).

198 ribute to thrombosis and miscarriages in the antiphospholipid syndrome (APS).

199 e the mid-1980s for diagnosing patients with antiphospholipid syndrome (APS).

200 ion and vascular thrombosis in patients with antiphospholipid syndrome (APS).

201 y with antiphospholipid antibodies is termed antiphospholipid syndrome (APS).

202 to promote thrombosis and fetal loss in the antiphospholipid syndrome (APS).

203 IgG anti-tPA antibodies in patients with the antiphospholipid syndrome (APS).

204 ) is the most common disease associated with antiphospholipid syndrome (APS).

205 ctly contribute to hypercoagulability in the antiphospholipid syndrome (APS).

206 Ab (aPL) and thrombosis is recognized as the antiphospholipid syndrome (APS).

207 )GPI) appear to be a critical feature of the antiphospholipid syndrome (APS).

208 s) effect thrombotic events in patients with antiphospholipid syndrome (APS).

209 the effect of antibodies from patients with antiphospholipid syndrome (APS).

210 Catastrophic antiphospholipid syndrome (CAPS) is a potentially lethal

211 Catastrophic antiphospholipid syndrome (CAPS) is characterized by his

212 e either purified IgG from patients with the antiphospholipid syndrome (IgG-APS) or normal IgG from h

213 G (IgG) isolated from either a patient with antiphospholipid syndrome (IgG-APS), a healthy control s

214 by The Nimes Obstetricians and Hematologists-Antiphospholipid Syndrome (NOH-APS) Study Group give us

215 ic lupus erythematosus (SLE) but not primary antiphospholipid syndrome (PAPS), a nonlupus systemic au

216 ere treated with IgG aPL (from patients with antiphospholipid syndrome [APS]) or with control IgG (fr

217 ective and safe alternative in patients with antiphospholipid syndrome and previous venous thromboemb

218 ive immune responses with innate immunity in antiphospholipid syndrome and systemic lupus erythematos

219 s, such as heparin-induced thrombocytopenia, antiphospholipid syndrome and thrombotic thrombocytopeni

220 otic mechanisms, women with purely obstetric antiphospholipid syndrome are at risk for thrombotic com

221 at cause anticoagulant-refractory thrombotic antiphospholipid syndrome are now better understood.

222 pathways involved in the vasculopathy of the antiphospholipid syndrome are unknown, and adequate ther

223 ndrome patient sera are not only a marker of antiphospholipid syndrome but are directly involved in t

224 Anticoagulant-refractory thrombotic antiphospholipid syndrome can be broadly defined as brea

225 dies purified from the sera of patients with antiphospholipid syndrome complicated by thrombosis grea

226 NT FINDINGS: Although the pathophysiology of antiphospholipid syndrome continues to be poorly underst

227 me that involves the injection of high-titer antiphospholipid syndrome human serum, complement activa

228 hile the 956A allele was associated with the antiphospholipid syndrome in patients with SLE (P = 0.00

229 s in the glomeruli, recapitulating the human antiphospholipid syndrome in these mice.

230 controversial issues in the treatment of the antiphospholipid syndrome include the use of less intens

231 The antiphospholipid syndrome is a disorder of recurrent thr

232 The antiphospholipid syndrome is a major feature of systemic

233 PURPOSE OF REVIEW: Antiphospholipid syndrome is a rare cause of ocular vaso

234 Antiphospholipid syndrome is an autoimmune disease chara

235 Antiphospholipid syndrome is characterized by recurrent

236 Antiphospholipid syndrome is characterized by thrombosis

237 Antiphospholipid syndrome is characterized by thrombosis

238 The antiphospholipid syndrome is characterized by thrombosis

239 The antiphospholipid syndrome is characterized clinically by

240 f thrombosis in the purely obstetric form of antiphospholipid syndrome is uncertain.

241 m, but whether it is useful in patients with antiphospholipid syndrome is uncertain.

242 ate clinical manifestations in patients with antiphospholipid syndrome may be established.

243 f the thrombin-reactive aCL in patients with antiphospholipid syndrome may bind to PC and APC.

244 rating intrarenal vessels from patients with antiphospholipid syndrome nephropathy showed indications

245 Patients with antiphospholipid syndrome nephropathy who required trans

246 essels of patients with primary or secondary antiphospholipid syndrome nephropathy.

247 related to systemic lupus erythematosus and antiphospholipid syndrome occur in association with mult

248 that anti-beta(2)-GP1 IgG autoantibodies in antiphospholipid syndrome patient sera are not only a ma

249 anti-cardiolipin mAbs derived from a primary antiphospholipid syndrome patient.

250 anticoagulation are similarly protective in antiphospholipid syndrome patients after the first throm

251 Catastrophic antiphospholipid syndrome patients usually receive a com

252 cells, IgG antibodies from patients with the antiphospholipid syndrome stimulated mTORC through the p

253 In the mouse model of antiphospholipid syndrome that involves the injection of

254 a(2)-GP1 autoantibodies from 3 patients with antiphospholipid syndrome were affinity-purified using h

255 in two UK hospitals, included patients with antiphospholipid syndrome who were taking warfarin for p

256 evated liver enzymes low platelets syndrome; antiphospholipid syndrome); or, ultimately, to diagnose

257 cted at a French referral center for SLE and antiphospholipid syndrome, 24 patients with SLE, with a

258 expansions in JPH3, a fourth patient with an antiphospholipid syndrome, and a fifth patient with B12

259 nts with systemic lupus erythematosus or the antiphospholipid syndrome, and a subset of such antibodi

260 y artery disease, peripheral artery disease, antiphospholipid syndrome, and cancer.

261 rs such as heparin-induced thrombocytopenia, antiphospholipid syndrome, and therapy with asparaginase

262 ts with systemic lupus erythematosus and the antiphospholipid syndrome, are associated with adverse p

263 lar risks, lupus nephritis, CNS disease, the antiphospholipid syndrome, assessment of disease activit

264 is is considered the cardinal feature of the antiphospholipid syndrome, chronic vascular lesions are

265 s such as those with severe renal failure or antiphospholipid syndrome, or cancer, respectively.

266 a (HIT), beta-2-glycoprotein-1 implicated in antiphospholipid syndrome, or red blood cells coated wit

267 t rejection, major trauma, severe burns, the antiphospholipid syndrome, preeclampsia, sickle cell dis

268 ative colitis, systemic lupus erythematosus, antiphospholipid syndrome, Sjogren syndrome, myasthenia

269 th the spectrum of clinical manifestation of antiphospholipid syndrome, the diagnostic criteria of th

270 k for developing thrombosis in patients with antiphospholipid syndrome, the majority of pathogenic aP

271 n documented as a biomarker for diagnosis of antiphospholipid syndrome, their direct role in the path

272 of the immunology and pathophysiology of the antiphospholipid syndrome, treating this condition remai

273 f polyclonal IgG purified from patients with antiphospholipid syndrome, using both solid-phase and fl

274 roquine and the statins for the treatment of antiphospholipid syndrome-associated clinical manifestat

275 ay hold promise as a therapeutic approach to antiphospholipid syndrome-associated pregnancy complicat

276 m explaining adverse obstetrical outcomes in antiphospholipid syndrome.

277 nia, thrombotic thrombocytopenia purpura and antiphospholipid syndrome.

278 dies promote atherosclerosis in persons with antiphospholipid syndrome.

279 a and beta(2)-glycoprotein-I (beta(2)GPI) in antiphospholipid syndrome.

280 new targets for therapeutic intervention in antiphospholipid syndrome.

281 ity of autoantibodies found in patients with antiphospholipid syndrome.

282 for therapy to prevent pregnancy loss in the antiphospholipid syndrome.

283 systemic lupus erythematosus or catastrophic antiphospholipid syndrome.

284 contribute to the prothrombotic diathesis in antiphospholipid syndrome.

285 criteria for diagnosis and treatment of the antiphospholipid syndrome.

286 ctively bound IgG derived from patients with antiphospholipid syndrome.

287 osclerosis in autoimmune disease such as the antiphospholipid syndrome.

288 re particularly relevant to Ags important in antiphospholipid syndrome.

289 ipid antibodies present in patients with the antiphospholipid syndrome.

290 ologic findings in patients with established antiphospholipid syndrome.

291 excluded patients with malignant disease and antiphospholipid syndrome.

292 ogenic aPL may be generated in patients with antiphospholipid syndrome.

293 sy specimens from patients with catastrophic antiphospholipid syndrome.

294 specimens from persons who had catastrophic antiphospholipid syndrome.

295 in the vascular lesions associated with the antiphospholipid syndrome.

296 mus in kidney-transplant recipients with the antiphospholipid syndrome.

297 ndard anticoagulant treatment for thrombotic antiphospholipid syndrome.

298 ose with systemic lupus erythematosus and/or antiphospholipid syndrome.

299 nt state in these diseases as well as in the antiphospholipid syndrome.

300 s positively correlated with the symptoms of antiphospholipid syndromes (APS), including thrombosis a